SFY 2021 - 2022 MC MLR Summary
HIV SNP line of business
| SFY 2021 - 2022 MC MLR Summary | |||||||
|---|---|---|---|---|---|---|---|
| HIV SNP line of business | |||||||
| Plan | MLR AFTER Credibility Adjustment |
Medical Expense (Total Numerator) |
Premium (Total Denominator) |
Remittance | Credible | MMs | |
| Amida Care Inc. | 89.61% | $435,922,516 | $497,472,426 | $0 | Partially Credible | 100,680 | |
| MetroPlus Health Plan, Inc. | 96.42% | $237,380,758 | $253,437,986 | $0 | Partially Credible | 55,644 | |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 95.83% | $184,180,623 | $199,407,628 | $0 | Partially Credible | 35,527 | |
| Total | $857,483,897 | $950,318,040 | $0 | 191,851 | |||
NOTES:
Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.
No remittance for plan if Non-Credible
